Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : India approves Russia's Sputnik V COVID-19 vaccine

04/12/2021 | 03:55pm EDT
FILE PHOTO: A medical specialist holds a vial of Sputnik V vaccine against the coronavirus in a department store in Moscow, Russia

NEW DELHI/MOSCOW (Reuters) - India has approved the use of Russian Sputnik V COVID-19 vaccine, the Russian Direct Investment Fund (RDIF) said on Monday, confirming earlier reports of its imminent endorsement.

India overtook Brazil to become the nation with the second highest number of infections worldwide after the United States, as it battles a second wave, having given about 105 million doses among a population of 1.4 billion.

The RDIF, which is responsible for marketing the vaccine abroad, said the Drug Controller General of India (DCGI) had approved the use of Sputnik V.

"India, the world's 2nd most populous nation, became the 60th country to register #SputnikV after positive results of local Phase 3 clinical study. Sputnik V is now authorized in 60 countries with population of over 3 bln people," a post on the Sputnik V official Twitter account said.

Earlier on Monday, two people familiar with the matter said the panel of the Central Drugs Standard Control Organisation (CDSCO) had recommended the authorisation.

The RDIF has signed deals to produce more than 750 million doses of Sputnik V in India with six domestic firms.

India has so far used two vaccines, one developed by AstraZeneca and Oxford University, and the other by domestic firm Bharat Biotech.

Sputnik V, developed by Moscow's Gamaleya Institute, has proved 91.6% effective against COVID-19 and has been approved for use in more than 50 countries.

The Indian drugs regulator did not respond to a request for comment on the expert panel's approval of the Russian vaccine.

Indian pharmaceutical firm Dr. Reddy's, which is marketing the vaccine in India, said it was awaiting formal word from the authorities.

"Dr. Reddy's and RDIF are working diligently with the Indian regulatory authorities to obtain the approval for Sputnik V. We are fully committed to playing our part in India's fight against COVID," the company said.

Shares of Dr Reddy's ended up 5% after the Economic Times newspaper first reported the news.

The firm has helped run a small domestic trial to test the vaccine's safety and ability to generate an immune response.

(Additional reporting by Rama Venkat and Shivani Singh in Bengaluru, Polina Ivanova and Vladimir Soldatkin in Moscow; Writing by Sachin Ravikumar; Editing by William Maclean and Angus MacSwan)

By Nigam Prusty and Krishna N. Das


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.72% 7735 Delayed Quote.5.61%
DR. REDDY'S LABORATORIES LIMITED 0.15% 5173.55 End-of-day quote.-0.59%
All news about ASTRAZENECA PLC
02:12pSome Countries Shift Guidance on AstraZeneca Vaccine
DJ
01:31pTHE LATEST : France welcomes EU curb on AstraZeneca vaccine
AQ
08:27aASTRAZENECA  : REFILE-UPDATE 2-EU has not ordered AstraZeneca vaccines beyond Ju..
RE
06:30aEU'S BRETON : EU did not renew Astrazeneca COVID-19 vaccine order for after June
RE
05/08EU Tepid on Biden Call to Waive Intellectual Property Rights for Covid-19 Vac..
DJ
05/08ASTRAZENECA  : Sri Lanka approves Pfizer COVID vaccine for emergency use
RE
05/08Who have provinces pegged to receive COVID-19 vaccines in the coming weeks?
AQ
05/07Correction to Impact of U.S. Support for Patent Waiver on Vaccine Makers Arti..
DJ
05/07ASTRAZENECA PHARMA INDIA  : Key EU countries rebuff Biden on sharing COVID vacci..
RE
05/07AstraZeneca Weighs Seeking Full U.S. Approval for Covid Shot, Skipping Emerge..
DJ
More news
Financials (USD)
Sales 2021 30 843 M - -
Net income 2021 4 552 M - -
Net Debt 2021 11 038 M - -
P/E ratio 2021 29,7x
Yield 2021 2,64%
Capitalization 142 B 142 B -
EV / Sales 2021 4,96x
EV / Sales 2022 4,42x
Nbr of Employees 76 100
Free-Float 95,8%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Average target price 130,07 $
Last Close Price 108,20 $
Spread / Highest target 53,4%
Spread / Average Target 20,2%
Spread / Lowest Target -12,1%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC5.61%142 034
JOHNSON & JOHNSON7.07%443 727
ROCHE HOLDING AG-1.88%289 958
PFIZER, INC.6.47%220 784
ABBVIE INC.8.03%204 279
MERCK & CO., INC.-4.14%198 539